Intranasal Protollin, a bacterial lipopolysaccharide derivative, shifted immune function in early Alzheimer's patients by enhancing monocyte clearing capacity while reducing cytotoxic T cell activity. This Phase 1 trial demonstrates a mechanism for redirecting neuroinflammation away from neurodegeneration without systemic immunosuppression.
Key Points
- Protollin increased monocyte phagocytic capacity in Alzheimer's subjects
- CD8+ T cell cytotoxicity decreased, suggesting reduced neural damage
- Nasal route delivered immune modulation without broad immunosuppression
Longevity Analysis
Early Alzheimer's involves a misdirected immune response where cytotoxic T cells contribute to neuronal loss while monocytes fail to clear pathogenic proteins efficiently. Protollin rebalances this dynamic by enhancing the brain's resident cleanup capacity and dampening the cellular attack on neural tissue. Rather than blocking immunity entirely, the intervention redirects it—a distinction that matters for long-term neurological resilience. The nasal administration route suggests direct access to brain-associated lymphoid tissue, positioning this as a targeted interference with the cascade that drives cognitive decline rather than a broad systemic intervention.
Original published by Nature - npj Aging, by Panayota Kolypetri.